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Risks and Benefits of Disease-Modifying Antirheumatic Treatment for
Systemic Lupus Erythematosus Exacerbations in Pregnant Women
Abstract
The direct correlation between systemic lupus erythematosus (SLE) and increased risk of disease activity
during pregnancy is concerning to both maternal health and fetal condition. Disease-modifying antirheumatic
drugs (DMARDS) have been shown to decrease disease activity in systemic lupus erythematosus (SLE)
patients and effectively treat exacerbations however treatment may increase risk of fetal demise due to
teratogenic effects. The potential benefits and harms to both maternal and fetal health upon taking disease-
modifying antirheumatic drugs (DMARDS) during pregnancy is a clinical question that has yet to be
answered, and recommendation of exacerbation treatments is currently being explored by practicing
physicians.
Background: Systemic Lupus Erythematosus (SLE) is a multi system autoimmune connective tissue disorder
that is more common in women of childbearing years. Majority of studies show an increased risk of disease
exacerbation during pregnancy which becomes life threatening for both mother and fetus, especially if
exacerbations are not treated, resulting in spontaneous abortion, stillbirth, preterm delivery, fetal growth
retardation, fetal loss rates, pre-eclampsia, and gestational hypertension. Main risk factors for adverse
pregnancy course and outcome are: active disease, nephritis with proteinuria, hypertension, and maternal
serum antibodies to SS-A/Ro, SS-B/La, cardiolipin, [beta]2-glycoprotein I and lupus anticoagulant. Studies
show that prevention and treatment of exacerbation during pregnancy is highly effective in lowering risk of
fetal demise, in fact although systemic lupus erythematosus (SLE) pregnancies are high risk, pregnancy
during inactive disease state has a high success rate of normal outcome. It is therefore essential to treat
symptoms of exacerbation as they appear in systemic lupus erythematosus (SLE) patients during pregnancy.
Exacerbations are effectively treated with disease-modifying antirheumatic drugs (DMARDS) however this
classification of drugs has been known to have teratogenic effects and therefore poses a concern to medical
providers in treating active disease during pregnancy.
Disease-modifying antirheumatic drugs (DMARDS) are commonly used in the treatment of systemic lupus
erythematosus (SLE) and have been shown to be extremely effective in the treatment of systemic lupus
erythematosus (SLE) exacerbations. The most commonly used disease-modifying antirheumatic drugs
(DMARDS) include: cyclophosphamide, methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine
(HCQ), and azathioprine (AZA). Treatments are often started at an early age therefore women of
reproductive age are at risk for exposure to disease-modifying antirheumatic drugs (DMARDS) at time of
conception and pregnancy. Due to lack of information and studies on the teratogenic effects of disease-
modifying antirheumatic drug (DMARDS) exposure to fetus during pregnancy, it makes treatment and safety
of medication exposure questionable. It has become increasingly important to investigate and explore the
benefits and risks in treating pregnant patients with disease-modifying antirheumatic drugs (DMARDS).
Objective: To explore current literature and investigate potential harms and benefits of using disease-
modifying antirheumatic drugs (DMARDS) treatments during systemic lupus erythematosus (SLE)
exacerbation during pregnancy, and provide clarity to treatment recommendations in this demographic.
Methods: An extensive review of literature was constructed using Ovid and PubMed in conjunction with
manually reviewing references cited from collected articles. Search words included: Systemic Lupus
Erythematosus (SLE), Pregnancy, Lupus exacerbation, Azathioprine (AZA), Sulfasalazine (SSZ),
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Methotrexate (MTX), Hydroxycholoroquine (HCQ), Cyclophosphamide, Disease modifying antirheumatic
drugs (DMARDS), lupus nephritis, and immunosuppression medications. Articles from 1997-2008 were
used in composing a thorough literature review of this topic. Four articles were extensively reviewed and
results were compared. Several complimentary articles of disease-modifying antirheumatic (DMARDS)
treatments during pregnancy were also compared and reviewed.
Results: Current literature review found that treatment with disease-modifying antirheumatic drugs
(DMARDS) is crucial in the treatment of lupus exacerbation during pregnancy however the potential benefits
and harms must be thoroughly reviewed before initialization of treatment. Review of the literature showed
that each individual drug of the disease-modifying antirheumatic drug (DMARDS) group had different
effects on the fetus and mother, therefore each drug was individually studied.
Studies showed that hydroxychloroquine (HCQ) is an extremely useful agent in managing certain aspects of
clinical systemic lupus erythematosus (SLE), showing that in small doses no fetal anomalies have been
identified, however at supratherapeutic doses there may be ocular or auditory damage.4 Studies also showed
that discontinuing hydroxychloroquine (HCQ) during pregnancy could possibly produce flares in patients
with systemic lupus erythematosus (SLE), which could then be detrimental to the pregnancy. There is limited
evidence that shows any benefit from initiating hydroxychloroquine (HCQ) therapy during pregnancy.
Studies showed that methotrexate (MTX) use during pregnancy is conflicting, a critical period and dose for
exposure is proposed, however high rates of pregnancy loss indicates risk to fetus. Therefore in each individual
patient, consideration regarding use before and during pregnancy has to be made.
Sulfasalazine (SSZ) is presently listed as a Category B drug on the FDA Pregnancy Risk Classification,
however further research needs to be done for safety of this medication. A limited amount of studies were
found regarding this medication, however the articles that were found showed no major teratogenic effects
upon women taking sulfasalazine (SSZ) during pregnancy.6
Studies of azathioprine (AZA) showed that upon standard doses of medications no increase risk of congenital
abnormalities were shown; however there were some contradictive studies that resulted in pregnancy loss
while on azathioprine (AZA) during active systemic lupus erythematosus (SLE) disease. It is indecisive if the
increase in pregnancy loss was due to active disease state or medication and therefore further studies are
needed to evaluate this factor.
Cyclophosphamide studies were found to show an increased risk of fetal malformation due to cell death in
utero. Several studies showed first trimester miscarriages upon exposure to cyclophosphamide. In the past,
cyclophosphamide recommendations were to avoid exposure to medication during the first and second
trimester due to fetal malformation, however recent studies now recommend avoiding during the third
trimester as well, due to intrauterine fetal demise upon exposure.
Conclusion: In conclusion disease-modifying antirheumatic (DMARDS) treatments are crucial in the
treatments of systemic lupus erythematosus (SLE) exacerbations; in accordance with use during pregnancy it
is important to evaluate the patient and the disease individually, weighing the benefits and harms to both the
mother and fetus. Recommended disease-modifying antirheumatic (DMARDS) treatment is based on
observational studies and known teratogenic effects of medications therefore each medication is individually
explored in its use for systemic lupus erythematosus (SLE) exacerbation. Review of literature strongly
indicates hydroxychloroquine (HCQ) for safe use during pregnancy as well as azathioprine (AZA) in treating
systemic lupus erythematosus (SLE) exacerbation during pregnancy. Studies indicated high risk of fetal
demise and/or teratogenic congenital abnormalities upon the use of methotrexate (MTX) and
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cyclophosphamide therefore use during pregnancy is not recommended. Sulfasalazine (SSZ) articles were
limited and recommendation of use was based on limited information, therefore more research is needed at
this time upon use during pregnancy. Overall, weighing potential benefits and harms to both the mother and
the fetus prior to establishing treatment of exacerbation during pregnancy is the primary importance in
treating exacerbations at this time.
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Abstract   
The direct correlation between systemic lupus erythematosus (SLE) and increased risk of 
disease activity during pregnancy is concerning to both maternal health and fetal 
condition. Disease-modifying antirheumatic drugs (DMARDS) have been shown to 
decrease disease activity in systemic lupus erythematosus (SLE) patients and effectively 
treat exacerbations however treatment may increase risk of fetal demise due to 
teratogenic effects. The potential benefits and harms to both maternal and fetal health 
upon taking disease-modifying antirheumatic drugs (DMARDS) during pregnancy is a 
clinical question that has yet to be answered, and recommendation of exacerbation 
treatments is currently being explored by practicing physicians.   
 
Background   
Systemic Lupus Erythematosus (SLE) is a multi system autoimmune connective tissue 
disorder that is more common in women of childbearing years.  Majority of studies show 
an increased risk of disease exacerbation during pregnancy which becomes life 
threatening for both mother and fetus, especially if exacerbations are not treated, resulting 
in spontaneous abortion, stillbirth, preterm delivery, fetal growth retardation, fetal loss 
rates, pre-eclampsia, and gestational hypertension.1 2 3 Main risk factors for adverse 
pregnancy course and outcome are: active disease, nephritis with proteinuria, 
hypertension, and maternal serum antibodies to SS-A/Ro, SS-B/La, cardiolipin, [beta]2-
glycoprotein I and lupus anticoagulant.3 Studies show that prevention and treatment of 
exacerbation during pregnancy is highly effective in lowering risk of fetal demise, in fact 
although systemic lupus erythematosus (SLE) pregnancies are high risk, pregnancy 
during inactive disease state has a high success rate of normal outcome. It is therefore 
essential to treat symptoms of exacerbation as they appear in systemic lupus 
erythematosus (SLE) patients during pregnancy. Exacerbations are effectively treated 
with disease-modifying antirheumatic drugs (DMARDS) however this classification of 
drugs has been known to have teratogenic effects and therefore poses a concern to 
medical providers in treating active disease during pregnancy.    
 
Disease-modifying antirheumatic drugs (DMARDS) are commonly used in the treatment 
of systemic lupus erythematosus (SLE) and have been shown to be extremely effective in 
the treatment of systemic lupus erythematosus (SLE) exacerbations.  The most commonly 
used disease-modifying antirheumatic drugs (DMARDS) include: cyclophosphamide, 
methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and azathioprine 
(AZA). Treatments are often started at an early age therefore women of reproductive age 
are at risk for exposure to disease-modifying antirheumatic drugs (DMARDS) at time of 
conception and pregnancy. Due to lack of information and studies on the teratogenic 
effects of disease-modifying antirheumatic drug (DMARDS) exposure to fetus during 
pregnancy, it makes treatment and safety of medication exposure questionable. It has 
become increasingly important to investigate and explore the benefits and risks in treating 
pregnant patients with disease-modifying antirheumatic drugs (DMARDS).    
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Objective 
 To explore current literature and investigate potential harms and benefits of using 
disease-modifying antirheumatic drugs (DMARDS) treatments during systemic lupus 
erythematosus (SLE) exacerbation during pregnancy, and provide clarity to treatment 
recommendations in this demographic.  
 
Methods 
An extensive review of literature was constructed using Ovid and PubMed in conjunction 
with manually reviewing references cited from collected articles. Search words included: 
Systemic Lupus Erythematosus (SLE), Pregnancy, Lupus exacerbation, Azathioprine 
(AZA), Sulfasalazine (SSZ), Methotrexate (MTX), Hydroxycholoroquine (HCQ), 
Cyclophosphamide, Disease modifying antirheumatic drugs (DMARDS), lupus nephritis, 
and immunosuppression medications.  Articles from 1997-2008 were used in composing 
a thorough literature review of this topic. Four articles were extensively reviewed and 
results were compared. Several complimentary articles of disease-modifying 
antirheumatic (DMARDS) treatments during pregnancy were also compared and 
reviewed. 
 
Results 
Current literature review found that treatment with disease-modifying antirheumatic 
drugs (DMARDS) is crucial in the treatment of lupus exacerbation during pregnancy 
however the potential benefits and harms must be thoroughly reviewed before 
initialization of treatment. Review of the literature showed that each individual drug of 
the disease-modifying antirheumatic drug (DMARDS) group had different effects on the 
fetus and mother, therefore each drug was individually studied.   
 
Studies showed that hydroxychloroquine (HCQ) is an extremely useful agent in 
managing certain aspects of clinical systemic lupus erythematosus (SLE), showing that in 
small doses no fetal anomalies have been identified, however at supratherapeutic doses 
there may be ocular or auditory damage.4 Studies also showed that discontinuing 
hydroxychloroquine (HCQ) during pregnancy could possibly produce flares in patients 
with systemic lupus erythematosus (SLE), which could then be detrimental to the 
pregnancy. There is limited evidence that shows any benefit from initiating 
hydroxychloroquine (HCQ) therapy during pregnancy.5 6      
 
Studies showed that methotrexate (MTX) use during pregnancy is conflicting, a critical 
period and dose for exposure is proposed, however high rates of pregnancy loss indicates 
risk to fetus. Therefore in each individual patient, consideration regarding use before and 
during pregnancy has to be made.6     
 
Sulfasalazine (SSZ) is presently listed as a Category B drug on the FDA Pregnancy Risk 
Classification, however further research needs to be done for safety of this medication. A 
limited amount of studies were found regarding this medication, however the articles that 
were found showed no major teratogenic effects upon women taking sulfasalazine (SSZ) 
during pregnancy.6  
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Studies of azathioprine (AZA) showed that upon standard doses of medications no 
increase risk of congenital abnormalities were shown; however there were some 
contradictive studies that resulted in pregnancy loss while on azathioprine (AZA) during 
active systemic lupus erythematosus (SLE) disease. It is indecisive if the increase in 
pregnancy loss was due to active disease state or medication and therefore further studies 
are needed to evaluate this factor.7    
 
Cyclophosphamide studies were found to show an increased risk of fetal malformation 
due to cell death in utero. Several studies showed first trimester miscarriages upon 
exposure to cyclophosphamide. In the past, cyclophosphamide recommendations were to 
avoid exposure to medication during the first and second trimester due to fetal 
malformation, however recent studies now recommend avoiding during the third 
trimester as well, due to intrauterine fetal demise upon exposure.8  
 
Conclusion 
In conclusion disease-modifying antirheumatic (DMARDS) treatments are crucial in the 
treatments of systemic lupus erythematosus (SLE) exacerbations; in accordance with use 
during pregnancy it is important to evaluate the patient and the disease individually, 
weighing the benefits and harms to both the mother and fetus. Recommended disease-
modifying antirheumatic (DMARDS) treatment is based on observational studies and 
known teratogenic effects of medications therefore each medication is individually 
explored in its use for systemic lupus erythematosus (SLE) exacerbation.  Review of 
literature strongly indicates hydroxychloroquine (HCQ) for safe use during pregnancy as 
well as azathioprine (AZA) in treating systemic lupus erythematosus (SLE) exacerbation 
during pregnancy. Studies indicated high risk of fetal demise and/or teratogenic 
congenital abnormalities upon the use of methotrexate (MTX) and cyclophosphamide 
therefore use during pregnancy is not recommended. Sulfasalazine (SSZ) articles were 
limited and recommendation of use was based on limited information, therefore more 
research is needed at this time upon use during pregnancy.  Overall, weighing potential 
benefits and harms to both the mother and the fetus prior to establishing treatment of 
exacerbation during pregnancy is the primary importance in treating exacerbations at this 
time. 
 
 
Keywords: Systemic Lupus Erythematosus (SLE), Pregnancy, Systemic Lupus 
exacerbation, Azathioprine (AZA), Sulfasalazine (SSZ), Methotrexate (MTX), 
Hydroxycholoroquine (HCQ), Cyclophosphamide, Disease modifying antirheumatic 
drugs (DMARDS), lupus nephritis, and immunosuppression medications1-24  
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Introduction 
Systemic Lupus Erythematosus (SLE) is a multi system autoimmune connective tissue disorder that is 
more common in women of childbearing years. It presents with various clinical presentations and can 
be life threatening when major organs are affected.10 16 Impact of pregnancy on systemic lupus 
erythematosus (SLE) activity has been debated in the published medical literature, however the 
majority of studies show an increased risk of disease exacerbation during pregnancy, meaning that 
some patients will experience dramatic worsening of symptoms that can possibly become life 
threatening for both the mother and the fetus.7 Fetal outcomes becomes jeopardized in lupus pregnancy 
with higher than normal rates of spontaneous abortion, stillbirth, preterm delivery, fetal growth 
retardation, fetal loss rates, pre-eclampsia, and gestational hypertension.1 2 3    
 
Disease-modifying antirheumatic drugs (DMARDS) are commonly used in the treatment of systemic 
lupus erythematosus (SLE) as well as many other autoimmune diseases and although they have been 
shown to be extremely effective in the treatment of systemic lupus erythematosus (SLE) exacerbation 
they have also been shown to have teratogenic effects. Disease-modifying antirheumatic drugs 
(DMARDS) are often started at an early age and therefore women of reproductive age are at risk for 
exposure to disease-modifying antirheumatic drugs (DMARDS) at time of conception as well as 
during pregnancy.  Due to increased disease activity during pregnancy, which has been shown to 
increase fetal demise, it is increasingly important to explore the benefits and risks in treating pregnant 
patients with disease-modifying antirheumatic drugs (DMARDS). 
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Background 
Systemic Lupus Erythematosus (SLE) is characterized by autoantibody production and a dysfunctional 
immune system resulting in organ inflammation and consequent damage.11 Systemic Lupus 
Erythematosus (SLE) is more prevalent in females, primarily African and Asian ancestry, occurring in 
about 1 per 700 women with a peak incidence around age 30.10 22 Systemic Lupus Erythematosus 
(SLE) has been found to have a complex genetic basis, with factors such as sunlight and medications 
being found to precipitate the condition, however causes of systemic lupus erythematosus (SLE) is 
unknown.10 It is estimated that approximately 2% of children will contract systemic lupus 
erythematosus (SLE) from their parents.8  
   
Diagnosis of systemic lupus erythematosus (SLE) is usually made upon presentation of constitutional 
symptoms, initiating a full hematological immunological work up which verifies diagnosis. The widely 
recognized presentation of a young woman with inflammatory arthritis and a butterfly rash is 
uncommon.  In fact non-specific symptoms are much more common such as: 
1. General Constitutional symptoms of fatigue, fevers, weight loss, malaise, headaches; 
2. Mucocutaneous symptoms such as oral ulcers, alopecia, photosensitive skin rashes, Raynaud’s 
phenomenon, discoid lupus, malar rash, subacute cutaneous lupus rash; 
3. Musculoskeletal manifestations such as arthralgia, polyarthritis, inflammatory myositis; 
4. Cardiopulmonary manifestations such as pleuritic chest pains, pericardial effusions, and 
pulmonary fibrosis; 
5. Hematological manifestations such as Coomb’s positive hemolytic anemia, leucopenia, 
lymphopenia, and thrombocytopenia; 
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6. Major organ involvement of renal system (lupus nephritis) or central nervous systems (strokes, 
seizures, coma, movement disorders, transverse myelopathy, demyelination syndromes and 
cognitive dysfunction) and antiphospholipid syndrome.3 10 11  
  
The American College of Rheumatology’s criteria for lupus diagnosis reports that 4 out of the 11 
criteria must be met for a diagnosis of systemic lupus erythematosus (SLE) to be made. A positive 
antinuclear antibody (ANA) test is a characteristic laboratory test used to help diagnose lupus however 
alone it has a poor predictive power and only has significance if the index of suspicion is high, based 
on clinical history and laboratory abnormalities.11 Immunological hallmark of systemic lupus 
erythematosus (SLE) is the presence of serum antibodies to an array of nuclear antigens, namely the 
antinuclear antibody (90% of patients will have positive ANA), but also the double stranded DNA (50-
80% of patients will have positive dsDNA), Smith (30% of patients will have positive Sm), 
ribonucleoprotein (RNP), SSP-A/Ro and SS-B/La antibodies (30% of patients) as well as 
anticardiolipin (ACL) and [beta]2-glycoprotein I (GPI) antibodies and lupus anticoagulant (LAC).3 17  
  
Systemic Lupus Erythematosus (SLE) exacerbations appear to be an innate immune response to DNA 
containing immune complexes. The response is mediated by the production of IFN –[alpha] and shift 
toward dominance of the Th2-cytokines, particularly IL-10. In normal pregnancy there is a shift to 
Th2-cytokine dominance, which is a physiological consequence of sex hormone induction of maternal 
immune tolerance to the fetus. Therefore, in patients affected by an underlying Th2-cytokine mediated 
autoimmune disease such as systemic lupus erythematosus (SLE), pregnancy may cause exacerbation 
of disease.3 Lupus flares are often characterized by specific laboratory abnormalities including elevated 
anti-double stranded DNA antibody titers and low complement (C3, C4, CH50) levels.11  More recent 
studies have found a two to threefold increase in systemic lupus erythematosus (SLE) activity during 
pregnancy, and based on these studies it appears that between 35% and 70% of all pregnancies will 
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have measurable systemic lupus erythematosus (SLE) activity.7 Women with active disease during 
pregnancy have been found to have a higher rate of adverse outcomes than those with inactive disease, 
especially with activity early in pregnancy.7 A study with 68 pregnancies being monitored found that 
four pregnancies were terminated due to severe active disease, three died in utero due to active 
maternal lupus, hypertension with placental abruption, and severe pre-eclampsia, and 27 were preterm 
pregnancies.2 With an increase risk of exacerbation and a risk of harm to both the fetus and the mother 
it is crucial to evaluate and weigh the benefits and risks of starting a disease modifying antirheumatic 
drug (DMARD) to control the disease state during pregnancy exacerbation.8    
  
Systemic Lupus Erythematosus (SLE) exacerbation has been shown to decrease in frequency during 
pregnancy if the disease has been inactive for 6 months prior to conception, however fetal loss and 
spontaneous abortion are still higher compared to control population.7 23 Risk increases in relation to 
the number of risk factors such as history of thromboembolism, lupus nephritis, renal failure, 
antiphospholipid antibody (APLA) syndrome, and active disease at conception; fetal growth is 
impaired when blood flow through the placenta is restricted by placental pathology, hypercoagulability 
and renal impairment which increases fetal wastage.3 11  Management of systemic lupus erythematosus 
(SLE) in pregnancy is a multidisciplinary effort including rheumatologists and obstetricians with 
experience in management of patients with systemic lupus erythematosus (SLE) and if indicated 
nephrologists depending on patient’s renal status.  Treatment of antiphospholipid antibodies (APLA), 
treatment of hypertension, and laboratory monitoring are crucial to the management of systemic lupus 
erythematosus (SLE) during pregnancy.8 22 It is important to diagnose a flare as it must be 
appropriately and aggressively managed to minimize maternal and fetal morbidity. The management 
spectrum is dependent upon symptoms but in more severe disease immunosuppression and intensive 
surveillance of mother and fetus are recommended; however, due to limited research on treatments it is 
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important to weigh potential benefits and harms to both the fetus and mother before initializing 
medications.16  
   
Disease Modifying Antirheumatic Drugs (DMARDS) 
Disease-modifying antirheumatic drugs (DMARDS) are commonly used in the treatment of systemic 
lupus erythematosus (SLE) exacerbation and maintenance of disease control. Disease-modifying 
antirheumatic drugs (DMARDS) include the following medications: adalimumab, azathioprine (AZA), 
hydroxychloroquine (HCQ), cyclosporine, D-penicillamine, etanercept, gold salts, infliximab, 
leflunomide, methotrexate (MTX), minocycline, and sulfasalazine (SSZ); and are used for 
immunosuppression particularly if the patient has major organ involvement such as lupus nephritis.11 
Several medications of the disease-modifying antirheumatic drug (DMARDS) class have been shown 
to possibly have teratogenic effects although information on their use in pregnancy is limited.  For 
obvious reasons randomized controlled trials hardly ever include pregnant women, as a consequence 
decisions in daily practice with respect to the use of disease-modifying antirheumatic drugs 
(DMARDS) in pregnancy are based on animal experiments, observation studies in humans, and expert 
opinion rather than analytical epidemiological studies such as case control surveillances or follow up 
studies.6 Due to the limited amount of information on disease-modifying antirheumatic (DMARDS) 
treatments it is important to review the potential benefits and effects to the fetus and the mother during 
a systemic lupus erythematosus (SLE) exacerbation upon using these medications during pregnancy.  
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Purpose of Study 
The purpose of this literature review is to explore the potential harms and benefits of using disease-
modifying antirheumatic (DMARD) treatments during a systemic lupus erythematosus (SLE) 
exacerbation during pregnancy, and provide clarity to treatment recommendations in this demographic. 
It has been found that systemic lupus erythematosus (SLE) is frequently exacerbated upon pregnancy, 
increasing risk of maternal and fetal demise if not treated; however, many of the disease modifying 
antirheumatic (DMARD) therapies have been found to show teratogenic properties also endangering 
the fetus. This literature review will evaluate the most commonly used disease-modifying 
antirheumatic (DMARD) treatments and their effects on pregnant women during exacerbations, as well 
as observational and case studies that provide recommended treatments for this demographic. 
 
Methods 
An extensive review of literature was constructed using Ovid and Pub Med in conjunction with 
manually reviewing references cited from collected articles. Search words included: Systemic Lupus 
Erythematosus (SLE), Pregnancy, Lupus exacerbation, Azathioprine (AZA), Sulfasalazine (SSZ), 
Methotrexate (MTX), Hydroxycholoroquine (HCQ), Cyclophosphamide, Disease modifying 
antirheumatic drugs (DMARDS), lupus nephritis, and immunosuppression medications.  Due to 
limited information on this topic, articles from 1997-2008 were used in composing a thorough 
literature review of this topic.  
  
This literature review is strongly based off four articles that individually explored the effects of 
disease-modifying antirheumatic (DMARD) treatments during pregnancy exacerbations. There were 
several articles that had recommendations of treatments due to case studies, observational studies, and 
prior animal studies that were also taken into consideration upon evaluation of this topic.   
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The first article is from 2006, “Disease-Modifying Antirheumatic Drugs in Pregnancy: Current Status 
and Implications for the Future.” This article was a literature review using EMBASE, the Cochrane 
Library and MEDLINE of manuscripts in the medical and pharmacological literature published in 
English between 1990 and 2004. All eligible publications were systematically scored for information 
on specific study design and outcome of the pregnancies such as live births, birth defects, miscarriages 
or abortions. Comments were noted regarding: 1 Type of birth defect; 2 Indication for which the 
medication was taken; 3 Follow up time after pregnancy; 4 Use of co-medications taken; 5 Follow-up 
time after pregnancy; 6 Use of co-medications; 7 Exposure time or period of the drug; 8 Miscellaneous 
findings.6  
 
The second article is from 2005, “Cyclophosphamide for Lupus during Pregnancy.”  This article was a 
chart review performed with Hopkins Lupus Cohort between 1986 and September 2003, in which 
obstetrical charts were obtained and reviewed to obtain a detailed history of each pregnancy and 
indication for cyclophosphamide. Pregnancies were evaluated prospectively for cyclophosphamide 
exposure, lupus activity, and fetal outcome; and comparisons were made between pregnancies with 
severe lupus requiring cyclophosphamide and those that did not.9  
 
The third article is from 2006, “Hydroxychloroquine in lupus pregnancy.” This article was a chart 
review from patients enrolled in Hopkins Lupus Pregnancy Cohort at Hopkins Lupus Center between 
1987 and 2002. The pregnancies were divided into 3 groups: no hydroxychloroquine (HCQ) exposure 
during pregnancy, continuous use of hydroxychloroquine (HCQ) during pregnancy, or cessation of 
hydroxychloroquine (HCQ) either in 3 months prior to or during first trimester or pregnancy. The 
pregnancy outcomes, fetal outcomes, and lupus activity during pregnancy were compared in these 
groups.4  
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The fourth article is from 2007, “Birth outcome in Women Treated with Azathioprine or 
Mercaptopurine during Pregnancy: A Danish nationwide cohort study.” This article obtained data on 
drug use and births from Danish population registries. The study was based on all women who filled 
prescriptions for Azathioprine (AZA) during pregnancy and delivered live born children between 
January 1996 and December 2001. Birth outcomes were compared to women who did not use 
azathioprine (AZA). Data on drug use and birth outcomes were obtained from Danish population 
registries and the Fertility Database Statistics Denmark was used to obtain information on all women 
who gave birth.15  
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Results 
Hydroxychloroquine (HCQ) 
Hydroxychloroquine (HCQ) is a disease-modifying antirheumatic drug (DMARD) that is used for mild 
cutaneous and musculoskeletal involvement and remains the mainstay for patient’s with mild systemic 
lupus erythematosus (SLE) especially those with arthralgia, skin rashes, alopecia, and oral/genital 
ulcerations.  It has proven to decrease risk of systemic lupus erythematosus (SLE) flare, improve 
prognosis of systemic lupus erythematosus (SLE) nephritis, and prevent death. It is also very well 
tolerated and arguably the best side effect profile of any medication available to treat systemic lupus 
erythematosus (SLE).7 Its use during pregnancy was initially concerning because of reports of 
congenital malformation including ocular and auditory damage, due to medication crossing the 
placenta and being present in breast milk8  However after an extensive literature review the consensus 
shows that hydroxychloroquine (HCQ) is an extremely useful agent in managing certain aspects of 
clinical systemic lupus erythematosus (SLE) and numerous studies have demonstrated that its use 
during pregnancy in small doses has shown to be safe.  Among 300 pregnancies described in literature 
that were exposed to hydroxychloroquine (HCQ) for treatment of an autoimmune disease showed no 
elevation of fetal anomalies identified, it has shown that when taken at supratherapeutic doses there 
may be ocular or auditory damage, however no such changes were seen among 133 babies exposed to 
hydroxychloroquine (HCQ) in utero.4 Studies show no increased risk of congenital malformations. 
Some studies did show that discontinuing hydroxychloroquine (HCQ) during pregnancy can possibly 
produce flares in patients with systemic lupus erythematosus (SLE), which could be detrimental to a 
systemic lupus erythematosus (SLE) pregnancy however there is also no evidence that suggests any 
benefit from initiating hydroxychloroquine (HCQ) therapy during pregnancy. 5 6   
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Methotrexate (MTX)  
Evidence regarding safety of methotrexate (MTX) during pregnancy is conflicting although a critical 
period and dose for exposure are proposed, high rate of pregnancy losses indicates risk to fetus and 
therefore in each individual patient consideration regarding use before and during pregnancy has to be 
made.6  Kozlowski et al. found no congenital anomalies among five live born children in a cohort of 
ten pregnancies, but the rate of spontaneous abortions was rather high (three of ten pregnancies).6  
Ostensen et al. reviewed four cases of methotrexate use during pregnancy and found three live born 
children without congenital malformations, and one woman had a miscarriage.6 Lewden et al described 
28 pregnancies exposed to methotrexate (MTX) and found 19 live births, of which one had minor 
neonatal anomalies, five were elective abortions, and four were spontaneous abortions.6 Donnenfeld et 
al showed in a series of case reports, ten healthy live births and four first trimester spontaneous 
abortions. The remaining case reports all reported fetuses with minor or major anomalies 6    
 
Sulfasalazine (SSZ)  
Sulfasalazine (SSZ) in a population based case control study (Norgard et al) showed no increased 
prevalence of congenital malformations among children born to women treated with sulfasalazine 
(SSZ) during pregnancy. The reported use of sulfasalazine (SSZ) during pregnancy was low (0.07%).6  
Although no major teratogenic effects were seen upon women taking sulfasalazine (SSZ), teratogenic 
effects still cannot be excluded due to lack of research on the medication. Presently it is listed as a 
Category B drug on the FDA Pregnancy Risk, however further research still needs to be done.6  
 
Azathioprine (AZA) 
Azathioprine (AZA) is indicated for moderate to severe disease, particularly for lupus nephritis and 
cerebritis. According to review of articles and literature of azathioprine (AZA) treatment among 
pregnant women using standard doses (2.5mg/kg/day) does not appear to increase risk of congenital 
 20 
abnormalities, in fact the drug may be especially valuable if renal disease is active during pregnancy.14  
The fetal liver does not have the enzyme required to metabolize azathioprine (AZA) into its active 
form therefore a series of pregnancies exposed to azathioprine (AZA) show no significant increase in 
fetal abnormalities and it has been said that it may be the safest immunosuppressant medication during 
pregnancy.7 In Hopkins Lupus Pregnancy Cohort 31 pregnancies were exposed to azathioprine (AZA) 
and among the women who conceived while taking azathioprine (AZA) and continued taking it 
through pregnancy, 2 of the 13 ended in pregnancy loss, both in women who had active systemic lupus 
erythematosus (SLE) during pregnancy. Among 10 women who maintained low lupus activity while 
taking azathioprine (AZA) throughout pregnancy all resulted in live births at greater than 34 weeks 
gestations.7 In the same study there was also an increase in pregnancy loss among woman who used 
azathioprine (AZA) to treat moderate to severe flare: of the 8 pregnancies with moderate to severe flare 
treated with azathioprine, five (63%) resulted in pregnancy loss, whereas only 1 of 9 (11%) had severe 
systemic lupus erythematosus (SLE) activity without azathioprine (AZA) treatment and suffered fetal 
lost.7  Similar to other disease-modifying antirheumatic drugs (DMARD) further studies are indicated 
in the evaluation of safety of azathioprine (AZA) during systemic lupus erythematosus (SLE) 
exacerbation treatment during pregnancy.  
 
Cyclophosphamide  
Cyclophosphamide is a disease-modifying antirheumatic drug (DMARD) that causes DNA-DNA 
cross- linking rendering the DNA inactive. This effect is most lethal to rapidly dividing cells, such as 
those in the immune system and the developing fetus. A threshold level of drug may be required to see 
malformations in exposed infants as only high doses of cyclophosphamide caused cell death and 
malformations.9 Cyclophosphamide is considered to be teratogenic and is classified as D in the 
Pregnancy Risk Category. Since 1990, only a few cases have been reported on the use of 
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cyclophosphamide during pregnancy; two cases reported a live born child, one case reported a child 
who died 12 days after birth and was diagnosed with a pattern of malformations referred to as 
cyclophosphamide embryopathy, and one case reported an unknown outcome. Vaux et al gave an 
overview of all cases reported in the literature between 1964 and 2003, and described craniofacial and 
limb defects, all reported cases had similar patterns of malformations.6 A recent study by Clowse et al 
showed that all four pregnancies exposed to cyclophosphamide resulted in first trimester miscarriage 
thus confirming its category D pregnancy risk status.6 Cyclophosphamide must be avoided during the 
first and early second trimester, however a recent study now believes it should be avoided even during 
the third trimester due to doses given that were followed by intrauterine fetal demise.8  
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A Review of the Literature 
Study one: 
1. Title: “Disease-Modifying Antirheumatic Drugs in Pregnancy: Current Status and Implications for 
the Future” 6  
 
2. Purpose of the Study: Study reviewed recent literature about disease modifying antirheumatic 
drugs (DMARD) used for rheumatic disease in pregnancy and described the type of study designs and 
results reported. The review underscores the gross absence of data on safety and risks of disease 
modifying antirheumatic drugs (DMARD) use during conception and pregnancy.  
 
3. Methods: A search using EMBASE, the Cochrane Library and MEDLINE, was conducted of 
original manuscripts in the medical and pharmacological literature published in English between 1990 
and 2004. The generic (adalimumab, anakinra, auranofin, sodium aurothiomalate, aurothioglucose, 
azathioprine, mercaptopurine, hydroxychloroquine, ciclosporin, cyclophosphamide, etanercept, 
infliximab, leflunomide, methotrexate, penicillamine and sulfasalazine) or brand names of all disease 
modifying antirheumatic drugs (DMARD) were used at the start of the search, and this search was 
refined with one of the following keywords or variations: ‘pregnant’, ‘pregnancy outcome’, ‘birth 
defects’, ‘malformations’ and ‘adverse outcome’ Primarily the search restricted to human studies and 
monotherapy in rheumatic disease, studies describing the use of antirheumatic drugs in other 
indications were not included.6  
 
4. Study Design: All eligible publications were systematically scored for information publications 
were systematically scored for information on specific study design (e.g. case reports, cohort study, or 
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RCT) and outcome of pregnancies (e.g. number of live births, birth defects, and miscarriages or 
abortions.) Comments were noted regarding (i.) the type of birth defect; (ii.) the indication for which 
the medication was taken; (iii.) the follow up time after pregnancy; (iv.) the use of co-medication; (v.) 
the exposure time or period of the drug; and (vi.) miscellaneous findings. 6   
 
5. Results: Twenty-nine studies were found; eight on hydroxychloroquine/chloroquine; thirteen on 
methotrexate (MTX), three on sulfasalazine (SSZ), and six on azathioprine (AZA) were identified. 
With respect to hydroxychloroquine (HCQ) most studies concluded that it could be safely used in 
systemic lupus erythematosus (SLE). None of the studies found an increased risk of congenital 
malformations. Five studies concluded that hydroxychloroquine (HCQ) could be safely used during 
pregnancy in treatment of systemic lupus erythematosus (SLE) and advised continuation of therapy 
during pregnancy rather discontinuation, however it must be noted that there is no evidence to suggest 
any benefit from initiating hydroxychloroquine (HCQ) therapy during pregnancy.6 The same 
conclusions were drawn from the azathioprine (AZA) studies, but the available evidence is scarce.  
One case report by Oefferlbauer-Ernst et al showed one healthy child after exposure to azathioprine 
(AZA) in utero. Heneghan et al and Alstead et al studied an exposed cohort, selected from a larger 
cohort, and concluded that the use of azathioprine (AZA) during pregnancy appeared to be generally 
safe.  
 
Evidence of methotrexate (MTX) during pregnancy is conflicting, with high rates of pregnancy losses 
indicates a risk to the fetus. Østensen et al. reviewed four cases of methotrexate (MTX) use during 
pregnancy and found three live-born children without congenital malformations, and one woman had a 
miscarriage. Lewden et al. described 28 pregnancies exposed to methotrexate (MTX) and found 19 live 
births, of which one had minor neonatal anomalies, five were elective abortions and four were 
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spontaneous abortions. Donnenfeld et al. showed, in a series of case reports, ten healthy live births and 
four first trimester spontaneous abortions (it was not reported if an autopsy was performed). The 
remaining case reports all reported fetuses with minor or major anomalies except for Feldkamp and 
Carey who described a healthy live birth. Feldkamp and Carey considered that a critical period of 
exposure to methotrexate (MTX) (>10mg weekly) exists at 6-8 weeks after conception. The guidelines 
of the American College of Rheumatology advise a female patient using methotrexate (MTX) to wait 
at least one ovulatory cycle after discontinuation before attempting to conceive due to its teratogenic 
potential. 6   
 
No major teratogenic effects of sulfasalazine (SSZ) were seen although teratogenic effects still cannot 
be excluded.  A population based control study by Norgard et al. showed no increased prevalence of 
congenital malformations among children born to women treated with sulfasalazine (SSZ) during 
pregnancy.6   
 
6. Conclusions: This review stresses the importance of good monitoring and further research of 
disease modifying antirheumatic (DMARD) treatment. For all other disease modifying antirheumatic 
drugs (DMARD) the information on their use in pregnancy was limited.  This review underscores the 
gross absence of data on safety and risks of disease modifying antirheumatic drug (DMARD) use 
during conception and pregnancy.  
 
7. Validity: This is a literature review, case study, that had a focused question and appropriate 
inclusion criteria for selection of articles. It is unlikely that relevant studies were missed and overall 
this study seems valid and applicable to the clinical setting.  
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Study Two: 
1. Title: “Cyclophosphamide for Lupus During Pregnancy.” 9  
 
2. Purpose of the Study: Study evaluated the effects of exposure to cyclophosphamide during 
pregnancy.  
 
3. Methods: Study reviewed pregnancies in patients with systemic lupus erythematosus (SLE) seen at 
a large university hospital using the Hopkins Lupus Cohort between 1986 and September 2003. 
Medical and obstetrical charts were obtained and reviewed, detailed history of each pregnancy and 
indication for cyclophosphamide were the focus. Pregnancies were evaluated prospectively for 
cyclophosphamide exposure, lupus activity, and fetal outcome. Comparisons were then made between 
pregnancies with severe lupus requiring cyclophosphamide and those that did not.9  
 
4. Study Design: Identified four pregnancies with cyclophosphamide exposure (two pregnancies were 
inadvertently exposed to cyclophosphamide early in the first trimester; and two patients were 
administered cyclophosphamide for severe lupus nephritis and thrombocytopenia during the second 
trimester.  The four exposed pregnancies were compared with 16 pregnancies that were identified to 
have had severe lupus during pregnancy but who did not receive cyclophosphamide.  Identified PEA 
(Physician Estimate of Activity) is a validated visual analog scale used to assess lupus activity (PEA, 0 
no disease; PEA 1, mild disease; PEA 2, moderate disease; PEA 3, most severe disease activity). This 
scale was used to evaluate and compare the two cohorts and their exacerbation activity.9   
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5. Results: This study identified four pregnancies with cyclophosphamide exposure; two pregnancies 
were inadvertently exposed to cyclophosphamide early in the first trimester; both resulted in first 
trimester miscarriages. Two pregnancies were inadvertently exposed to cyclophosphamide when 
mother became pregnant in the midst of receiving monthly doses of IV cyclophosphamide for 
glomerulonephritis; one woman suffered a miscarriage in 13th week of gestation and the other had an 
incomplete spontaneous abortion followed by dilation and curettage at nine weeks.9   
 
Two patients were administered cyclophosphamide for severe lupus nephritis and thrombocytopenia 
during the second trimester and soon after exposure to medication their pregnancies ended in fetal 
demise. The first woman presented to clinic in gestational week 17 with severe nephrotic syndrome, 
she had been treated with azathioprine (AZA), corticosteroids, and labetolol but was not improving, 
and was admitted to hospital at week 21 with severe HTN, anemia, thrombocytopenia, 
hypocomplementemia, and proteinuria. She was given IV cyclophosphamide, and although fetal 
ultrasounds and fetal monitoring during hospitalization were previously normal, an ultrasound done the 
next day revealed fetal demise. The second woman presented similarly early in second trimester with 
increasing proteinuria, vitiligo, HTN, hypocomplementemia, new malar rash, and severe vasculitic 
rash over her chest and breasts. She went on to develop renal insufficiency, elevated liver enzymes, 
anemia, thrombocytopenia, and myositis; and was given cyclophosphamide orally. Intrauterine fetal 
demise occurred on the seventh day of therapy, despite having several normal fetal ultrasounds in 
previous two weeks. After delivery she had a complicated course of hemodialysis, multiple intubations 
for volume overload, deep vein thrombosis, severe hypertension, asystolic arrest, vocal cord paralysis, 
and stroke resulting in her death six months post partum having never left the hospital.9  
 
 27 
The Study also identified 16 pregnancies from Hopkins Lupus Cohort with severe lupus during 
pregnancy but who did not receive cyclophosphamide. The live birth rate for pregnancy without 
exposure was 68.75% versus no live birth after exposure. 9  
 
6. Conclusions: Study concluded that fetal survival is strongly in doubt when cyclophosphamide is 
required to treat systemic lupus erythematosus (SLE) during pregnancy. Whether the risk is incurred 
because of severity of lupus or the toxicity of the medication is not clear. Current practice when 
treating with cyclophosphamide is to delay use of this drug until the baby can be delivered, 
prematurely if needed by using high dose prednisone, azathioprine (AZA), and occasionally 
cyclosporine. If not, the high-risk of fetal demise should be discussed with patient prior to 
administration. 9  
 
7. Validity: This is a literature review, case study that had a focused question and appropriate 
inclusion criteria for the selection of articles (charts). It is unlikely that important relevant studies were 
missed due to the database that was being used; it was narrowed down to one specific hospital 
increasing the validity of results. The results were homogeneous from study and study, and overall this 
study was valid and applicable to the clinical setting. 
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Study Three 
1. Title: “Hydroxychloroquine in Lupus Pregnancy.” 
 
2. Purpose of the Study:  Study was to examine systemic lupus erythematosus (SLE) activity and 
pregnancy outcomes in women with systemic lupus erythematosus (SLE) exacerbations treated or not 
treated with hydroxychloroquine (HCQ) during pregnancy.4 
 
3. Methods of Study: Study was a prospective study of pregnancies in women with systemic lupus 
erythematosus (SLE) who were evaluated between 1987 and 2002 enrolled in the Hopkins Lupus 
Pregnancy Cohort at Hopkins Lupus Center.  Pregnancies were divided into three groups: no 
hydroxychloroquine (HCQ) exposure during pregnancy, continuous use of hydroxychloroquine (HCQ) 
during pregnancy, or cessation of hydroxychloroquine (HCQ) either in 3 months prior to or during first 
trimester of pregnancy. The pregnancy outcomes, fetal outcomes, and lupus activity during pregnancy 
were compared among these groups.4  
 
4. Study Design: Cohort included 257 pregnancies evaluated in 197 women between 1987 and 2002. 
At first visit the patients’ lupus and obstetric history and medications taken prior to and during 
pregnancy were recorded. Visits were generally every 4-6 weeks throughout pregnancy. PEA and 
SLEDAI (validated and widely used measure of lupus activity) were used for evaluation. Defined a 
score of >4 as evidence of clinically important lupus activity during pregnancy.4   
 
5. Results: The rates of miscarriage, stillbirth, pregnancy loss, and congenital abnormality were not 
statistically different among the 3 groups. The degree of lupus activity during pregnancy was 
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significantly higher in women who stopped taking hydroxychloroquine (HCQ), as measured by the 
PEA and SLE disease activity index. In this study there were no fetal abnormalities clearly attributable 
to hydroxychloroquine (HCQ) exposure. Among 79 offspring born to women with hydroxychloroquine 
(HCQ) exposure, 1 child had a cleft lip and palate, 1 developed pneumonia and pleural effusions 
following birth, and another had mild rectal bleeding, all of these resolved with medical treatment. 4  
 
6. Conclusions: This study recommended the continuation of hydroxychloroquine (HCQ) treatment 
during pregnancy due to the absence of fetal toxicity. The cessation of hydroxychloroquine (HCQ) 
treatment during pregnancy could in fact increase the degree of lupus activity. Recommendations 
based on this study encourage the continuation of hydroxychloroquine (HCQ) treatment in women 
who are taking the drug at time of conception.4    
 
7. Validity: Study had clearly identified comparison groups that were similar with respect to important 
determinants of outcome, as well as the outcome and exposures measured. It seems that follow up was 
sufficiently long enough and complete in evaluating the effects on hydroxychloroquine (HCQ) on both 
the fetus and mother.  It seems that the results are overall valid and applicable to the clinical setting.  
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Study Four:  
1. Title: “Birth Outcome in Women Treated with Azathioprine or Mercaptopurine During Pregnancy: 
A Danish Nationwide Cohort Study.” 
 
2. Purpose of Study: Study examined the risk of adverse birth outcome among newborns of women 
exposed to azathioprine or mercaptopurine during pregnancy.15 
 
3. Methods: This Danish nationwide cohort study was based on all women who filled prescriptions for 
azathioprine (AZA) during pregnancy and delivered live born children between January 1996 and 
December 2001. Birth outcomes were compared to women who did not use azathioprine (AZA). Data 
on drug use and birth outcomes were obtained from Danish population registries and used the Fertility 
Database Statistics to obtain information on all women who gave birth. 15   
 
4. Design of Study: Included 76 exposed pregnancies in 69 women; of those, they used 64 pregnancies 
exposed 30 days before conception or during the first trimester to examine the risk of congenital 
abnormalities; and 65 pregnancies exposed during the entire pregnancy to examine preterm birth and 
low birth weight at term. The study was split into three groups: group one was the early pregnancy 
group (exposure early or prior to conception), group two was the entire pregnancy group during first 
through third trimesters, and group three was comprised of all children born between January 1996 and 
December 2001 to women who were treated with azathioprine (AZA) before pregnancy but not during 
pregnancy 15  
 
5. Results: Women exposed to azathioprine (AZA) had a higher risk of adverse birth outcomes than 
unexposed controls, however when the comparison was limited to newborns of women with same 
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types of underlying disease, relative risk for spontaneous and induced preterm birth, low birth weight 
at term and congenital abnormalities were seen. In the entire pregnancy group there were 17 preterm 
deliveries (26.2%) nine of these were induced (52.9%); in comparison only eight of 59 preterm 
deliveries were induced in the matched comparison cohort (13.6%). About 75% of all births from renal 
transplant recipients were preterm. 15  
 
6. Conclusion:  Study results suggest that adverse birth outcomes were caused by the underlying 
disease rather than by the use of azathioprine (AZA).  There was an increased risk of preterm birth 
among women who filled prescriptions for azathioprine (AZA) during pregnancy, compared with 
women who were not prescribed any kind of reimbursable medication during the period extending 
from 3 months prior to conception to the end of pregnancy. Data also indicated an increased risk of 
low birth weight and cancer for newborns of azathioprine (AZA) exposed women, however the 
underlying disease of concurrent use of other drugs may confound it. In the third comparison cohort in 
an attempt to take the underlying disease into consideration the association became weaker for induced 
preterm birth and disappeared for spontaneous preterm birth, low birth weight at term, and cancers 
implying that the adverse birth outcome were caused by the underlying disease and not by use of 
azathioprine (AZA).15 
 
7. Validity: The strengths of this study and its population design was made possible by Denmark’s 
uniformly organized national healthcare system, and the minimization of selection through use of 
exposure data from a complete nationwide prescription database. Another strength is that measurement 
of exposure was based on prescriptions rather than self reported use, which may lead to recall bias 
under ascertainment. Weaknesses of study include lack of information on patient compliance, filling 
prescription used as a proxy for actual drug use.  Overall the results seem valid and applicable to the 
study. 
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Recommendations  
Upon extensive review of articles and literature regarding proper treatment for systemic lupus 
erythematosus (SLE) exacerbations during pregnancy it has been found that overall the treatment of 
choice is dependent upon weighing the benefits and harms for each individual patient at time of 
exacerbation. Disease-modifying antirheumatic drugs (DMARDS) have been found to be extremely 
effective in treating systemic lupus erythematosus (SLE) exacerbations, however the may be harmful 
to the fetus upon exposure.  Due to the mortality that can occur during active disease, disease-
modifying antirheumatic (DMARD) treatment is sometimes necessary regardless of effects it may have 
on fetus, because without treatment maternal death may occur if active disease begins affecting vital 
organs. Therefore, discussion of potential effects and harm on both the mother and the fetus is 
important to discuss with the patient and family prior to pregnancy and initialization of medications.  
 
Prevention of active disease during pregnancy is crucial to both the mother and the fetus and therefore 
patient should be counseled about appropriate timing for planned pregnancy.  It has been found that 
during remission of at least 6 months’ duration when the patient is free of immunosuppressive 
medication is the appropriate time for mother to conceive.3 Pregnancy should be followed by an 
obstetrician and a rheumatologist, and possibly a nephrologist if kidneys have been affected by disease.  
Proper monitoring of labs and clinical examinations should be maintained during the entire course of 
the pregnancy, and medical providers should be trained in high-risk pregnancies, being able to 
decipher systemic lupus erythematosus (SLE) exacerbation symptoms from regular pregnancy 
complications. Symptomatic treatment is recommended before the initialization of disease-modifying 
antirheumatic (DMARD) treatment such as anti-inflammatories for arthralgias and blood pressure 
medications for HTN.  
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After extensive review of literature, it has been found that Hydroxychloroquine (HCQ) is a safe disease 
modifying antirheumatic drug (DMARD) to use during pregnancy showing no fetal abnormalities upon 
exposure. Recommendation of azathioprine (AZA) treatment during pregnancy throughout literature 
review found it to be safe during systemic lupus erythematosus (SLE) exacerbation in pregnant 
women.7 Methotrexate (MTX), Cyclophosphamide, and Sulfasalazine (SSZ) were all found to have 
high rates of fetal abnormalities or demise upon exposure during pregnancy. Although abnormalities 
were found upon exposure of these medications the literature was limited, and therefore further 
research was recommended in the treatment of systemic lupus erythematosus (SLE) exacerbations 
while pregnant when using this medications.  
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Conclusion 
In conclusion it is found that Systemic Lupus Erythematosus (SLE) is a serious multi system 
autoimmune connective tissue disorder that more commonly affects women of childbearing years, and 
can become life threatening to both mother and fetus during pregnancy if active disease is present and 
not treated. Disease-modifying antirheumatic (DMARD) treatments have been found to be extremely 
effective in treating active disease symptoms and upon extensive research have been found that for 
mild active disease hydroxychloroquine (HCQ) and azathioprine (AZA) are safe to use during 
pregnancy, having no fetal abnormalities or fetal demise reported in studies; however in moderate to 
severe disease, disease-modifying antirheumatic (DMARD) treatments with methotrexate (MTX), 
sulfasalazine (SSZ), and cyclophosphamide have shown to increase risk of spontaneous abortion and 
fetal abnormalities. Due to the wide spectrum of systemic lupus erythematosus (SLE) exacerbation, 
presentation is crucial and each patient’s situation should be evaluated individually when preparing to 
initialize disease-modifying antirheumatic (DMARD) treatment.  Although further research is needed 
to evaluate the effects of disease-modifying antirheumatic (DMARD) on pregnancy, an extensive 
literature review has individually evaluated each medication and its potential effects on both the fetus 
and the mother. Using what we know about this class of medications, medical providers can efficiently 
weigh potential risks and benefits of disease-modifying antirheumatic (DMARD) treatments during 
systemic lupus erythematosus (SLE) exacerbation in pregnant women, and discuss treatment options 
with the patient.   
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Tables 
Table I. Disease Modifying Antirheumatic Drugs   
  Whether it can be used in 
Drug  Evidence  Pregnancy  Breastfeeding  
HCQ No increased risk of miscarriage, congential 
malformation, or stillbirth at doses used in 
rheumatic diseases. Cessation increases risk of flare, 
and a long half life means that stopping does not 
prevent fetal exposure 
Yes  Yes 
Azathioprine  Fetus lacks enzyme to convert active form Yes Yes 
Ciclosporin  No increase in congenital malformation  
Trend towards prematurity and intrauterine growth 
restriction not significant and probably related to 
more severe maternal disease 
Yes If benefits 
outweighs risks 
Cyclophosphamide Alkylating agent  
Teratogenic and fetotoxic  
Risk of suppression of neonatal haemotopoiesis  
No (stop three  
months before 
conception) 
No  
Methotrexate Folate antagonist  
Teratogenic and fetotoxic  
No (stop three 
months before 
conception, and 
give folic acid 
throughout 
pregnancy) 
No  
Adapted Reference 6, 20  
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Table II. DMARDS and Pregnancy and HCQ and CQ  
 
 
 
Adapted from Reference 6  
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Table III. DMARDS and Pregnancy: Studies of Sulfasalazine 
 
Adapted from Reference 6  
 
 
Table IV DMARD and pregnancy studies of Azathioprine/Mercaptopurine  
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Adapted Reference 6  
 
 
 
 
Table V First Trimester Exposure to Cyclophosphamide 
 Pregnancy 1  Pregnancy 2  
Age  26 30 
Race African American  African American  
Prior pregnancy 
outcomes 
• Two full term deliveries  • One full term delivery  
• Two elective abortions  
 
Lupus History  • Eight years of SLE  
• Lupus Nephritis  
• Malar rash, mouth ulcers, alopecia, 
arthritis, pleurisy, anemia, 
leucopenia  
 
• One year of SLE  
• Lupus nephritis  
• Pleurisy, arthritis  
Anti-Phospholipid 
antibody status  
• Positive aCL antibodies, negative 
lupus anticoagulant  
• No prior pregnancy losses or 
thrombosis  
• Negative aCL and lupus anticoagulant  
• Renal vein thrombosis  
Indication for 
cyclophosphamide 
• Diffuse proliferative 
glomerulonephritis (WHO class 
IV) 
• Diagnosed two months prior to 
pregnancy  
• Membranous and mesangial glomerulonephritis 
(WHO class Vb) 
• Diagnosed six months prior to pregnancy  
24 hour protein 
during pregnancy  
1.5 g  3.3g 
Timing of IV 
Cyclophosphamide in 
pregnancy  
Day 16 of pregnancy  
(Two days after conception)  
Day 21 of pregnancy  
(Seven after conception)  
 
Other medications  Prednisone 15mg qd  Prednisone 30mg qd, Warfarin, captopril, albuterol, 
inhaled triamcinolone, irbesartan, metolazone, 
furosemide  
Pregnancy Outcome Miscarriage in week 13  Miscarriage in week 9  
Adapted from Reference 9  
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Table VI Second Trimester Exposure to Cyclophosphamide 
 Pregnancy 3 Pregnancy 4 
Age  25 28 
Race African American  African American  
Prior pregnancy 
outcomes 
• One spontaneous abortion first 
trimester abortion  
• Three elective abortions  
• One termination for fetal anomalies and active 
lupus 
• One elective abortion  
Lupus History  • Two years of SLE  
• Discoid lupus, malar rash, and 
arthritis, mouth ulcers 
• Malar rash, arthritis, lupus nephritis  
Anti-phospholipid 
antibody status  
• Negative aCL and lupus 
anticoagulant  
• No thrombosis  
• Positive aCL IgM, negative aCL IgG 
• False positive RPR  
Indication for 
cyclophosphamide 
• Lupus nephritis started in first 
trimester:24 hour urine protein: 
19.2 g; Serum creatinine: 53–124 
mmol/L Biopsy after pregnancy: 
diffuse proliferative GN 
• Thrombocytopenia to 34 000 
• Anemia with HCT of 16.3. 
• Microangiopathic hemolytic 
anemia 
• Cardiomyopathy: ejection fraction 
of 35% 
• Low complement 
• Anti-dsDNA titer 1:640 
• Lupus nephritis worsened over pregnancy 24 
hour urine protein: 3.5 g Serum creatinine: 44–
336 mmol/L 
• Thrombocytopenia to 11 000 
• Anemia with HCT of 17.4 
• Microangiopathic hemolytic anemia 
• Severe hypertension 
• Myositis with CK of 635 
• Low complement 
• Negative dsDNA antibody 
• New vitiligo and malar rash 
Cyclophosphamide 
dose/timing during 
pregnancy  
IV 250 mg/m2 during week 22 plus IV 
mesna 
PO 2 mg/kg/day starting week 20 
Other medications 
during pregnancy 
• Methylprednisolone 1g IV 
• Prednisone 40 mg qd 
• Hydroxychloroquine 400 mg  
• ASA 81 mg 
• Azathioprine 200 mg qd (in 
second trimester) 
• Labetalol, furosemide, fluticasone, 
salmeterol 
• Methylprednisolone 1 g IV 
• Prednisone 60 mg qd 
• Azathioprine 150 mg qd 
Pregnancy Outcome • Intrauterine fetal demise the day 
after cyclophosphamide 
administration  
• Intrauterine fetal demise seven days after 
starting cyclophosphamide.  
• The patient died six months post partum from 
complications of lupus flare 
Adapted Reference 9  
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Table VII Comparison of pregnancies with severe lupus requiring cyclophosphamide and not 
requiring cyclophosphamide  
 
 
 
Severe Lupus, no 
cyclophosphamide  
Severe lupus, cyclophosphamide  
Total pregnancies  16 2  
Live Births  11 (68.75%) 0  
Perinatal mortality (loss after 20 wks 
gestation) 
3 (18.75%) 2 (100%) 
Miscarriage (loss before 20 wks 
gestation) 
2 (13%) 0 
Ethnicity: African American 
Caucasian  
9 (56%) 
7 (44%) 
2 (100%) 
0 
Maternal Age:  
<25 
25-35 
>35 
 
4 (25%) 
12 (75%)  
0 
 
0 
2 (100%) 
0 
Years of SLE:  
Dx in pregnancy  
<5 years  
>5 years  
 
5 (31.25%) 
5 (31.25%) 
6 (37.5%) 
 
0 
1 (50%) 
1 (50%)  
Prior total pregnancies  4: no prior pregnancies  
12: > 1 prior pregnancies  
2: >1 prior pregnancy  
Anti-phospholipid antibody 
syndrome 
1 (6.25%) 0 (0)  
Prior renal lupus  9 (56.25%) 1 (50%)  
Proteinuria >500mg/24 hours in 
pregnancy  
14 (87.5%) 2 (100%)  
Pre-eclampsia  5 (31.25%) 0  
Hypertension (over 140/90) 11 (68.75%) 2 (100%)  
Thrombocytopenia (platelets >150) 5 (31.25%) 2 (100%)  
Low complement levels (C3 and/or 
C4) 
8 (50%) 2 (100%) 
Positive dsDNA antibodies  8 (50%) 1 (50%) 
Azathioprine in pregnancy  7 (43.75%) 2 (100%) 
Prednisone >40mg in pregnancy 13 (81.25%) 2 (100%) 
Adapted from reference 9  
 
 
Table VIII Miscarriage rate for all pregnancies seen in the Hopkins Lupus Center prior to 20 
weeks gestation 
Group 1, no HCQ  6/139 (4)  
Group 2, HCQ continued  7/52 (13)  
Group 3, HCQ stopped  4/37 (11)  
P values  0.24  
Adapted Reference Adapted from reference 4  
 
 
 41 
Table IX Demographic Characteristics and Lupus History of HCQ Study  
 Group 1, no HCQ Group 2, HCQ 
discontinued  
Group 3, HCQ stopped  
Total pregnancies  163 56 38 
Gestational age at first visit: 
0-9 weeks 
10-19 weeks 
20-29 weeks 
>30 weeks  
 
77 (47)  
62 (38) 
20 (12)  
4 (2)  
 
35 (63) 
17 (30) 
3 (5) 
1 (2)  
 
24 (63) 
13 (34) 
1 (3) 
0  
Ethnicity  
Caucasian 
African American  
Asian  
Hispanic  
Unknown   
 
98 (60) 
61 (37) 
4 (2)  
0  
0  
 
35 (63) 
16 (29) 
3 (5) 
1 (2) 
1 (2)  
 
23 (61) 
15 (39) 
0 
0 
0 
Age 
<25 years  
>25-34 years  
>35 years  
 
29 (18) 
109 (67)  
25 (15)  
 
7 (12) 
38 (68)  
11 (20)  
 
11 (29)  
22 (58)  
5 (13)  
Duration of SLE  
Dx during pregnancy  
<5 years  
>5 years  
 
30 (18)  
58 (36)  
75 (46)  
 
3 (5)  
18 (32)  
35 (63)  
 
2 (5)  
18 (48)  
18 (47)  
Antiphospholipid syndrome 23 (14)  3 (5)  0  
Year of Delivery  
Before 1995  
After 1995 
 
89 (55) 
74 (45)   
 
10 (18) 
46 (82)   
 
30 (79)  
8 (21)  
History of lupus nephritis  66 (40)  20 (36) 19 (50)  
High Activity lupus in the 6 
months prior to 
conception/no. of women 
seen in the prior 6 months  
 
8/52 (15)  
 
0/29  
 
4/14 (29)  
Adapted from reference 4  
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Table X Outcome for all pregnancies that survived past 20 weeks gestation 
 Group 1, no 
HCQ 
Group 2, HCQ 
continued  
Group 3, HCQ 
stopped  
P value  
Total pregnancies  157 49 34  
Live Births  145 47 32  
Stillbirth (pregnancy 
loss after >20 weeks) 
13(8) 3 (6) 3 (9) 0.85 
Preterm births  
Extreme (20-27.9 week) 
Preterm (28-36.9 weeks)  
 
15 (10) 
49 (31) 
 
 
6 (12) 
13 (27) 
 
2 (6) 
16 (47) 
 
0.83 
0.87 
Full term birth 
 >37 weeks 
93 (59) 30 (61)  16 (47)  0.98 
Small for gestational age 
(>10th percentile for age) 
among live births  
29 (20)  11 (24)  7 (23)  0.93 
Adapted from reference 4  
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